Publications by authors named "Jeffeny DE Los Santos"
Article Synopsis
- * The study found that anemia linked to higher risks for all-cause and cardiovascular hospitalizations, with significant statistics demonstrating this correlation.
- * Despite the correlation, when adjusting for age and other factors, anemia was mainly associated with an increased hazard for hospitalizations rather than mortality, highlighting the need for more research on how treating anemia might improve patient outcomes.
Article Synopsis
- The study examines the clinical outcomes of 419 patients diagnosed with transthyretin cardiac amyloidosis (ATTR-CA) from 2001 to 2021, focusing on changes in diagnosis and treatment over time.
- It found that more recent patients are generally older, have less severe disease, and are more likely to be treated with tafamidis, which significantly improves survival rates compared to earlier diagnosed patients.
- Key results show that a higher Columbia score indicates a greater risk of mortality or need for heart transplantation, while tafamidis notably decreases this risk, highlighting the importance of early treatment.
Article Synopsis
- Transthyretin cardiac amyloidosis (ATTR cardiac amyloidosis) affects older adults and can cause gait abnormalities, yet there is limited research focused on this demographic.
- A study involving 28 older males with ATTR cardiac amyloidosis and 11 healthy controls found significant differences in gait patterns, with the patients demonstrating slower, narrower, and shorter strides.
- Despite the gait differences observed in ATTR cardiac amyloidosis patients, these variations did not correlate with the severity of their clinical condition, indicating that gait analysis can be a useful tool for assessing falls risk and improving patient care.
Article Synopsis
- - Technetium-labeled radiotracers like Tc-99m PYP are used to diagnose transthyretin cardiac amyloidosis (ATTR-CA), but the significance of its uptake outside the heart (extracardiac uptake) is not well understood.
- - In the SCAN-MP study, primarily involving Black and Hispanic participants over 60 with heart failure, researchers found that 11.1% of subjects had extracardiac Tc-99m PYP uptake, with kidney and bone uptake being the most common.
- - Despite the discovery of extracardiac uptake in these participants, only 1.1% had findings that were clinically actionable, indicating that most of the uptake was not significant for further
Article Synopsis
- Black patients experience higher stroke rates than White patients despite having lower rates of atrial fibrillation (AF), with White patients diagnosed with AF at significantly higher rates.
- A study involving 558 ATTR-CA patients revealed that Black patients with AF faced a much greater risk (hazard ratio of 5.78) for thromboembolic events compared to their White counterparts.
- The research indicates that treatment discrepancies, such as lower rates of anticoagulation and issues with maintaining therapeutic ranges, may contribute to these increased risks among Black patients.*
Aims: Although systemic embolism is a potential complication in transthyretin amyloid cardiomyopathy (ATTR-CM), data about its incidence and prevalence are scarce. We studied the incidence, prevalence and factors associated with embolic events in ATTR-CM. Additionally, we evaluated embolic events according to the type of oral anticoagulation (OAC) and the performance of the CHA DS -VASc score in this setting.
View Article and Find Full Text PDFArticle Synopsis
- The Val122Ile variant of transthyretin (TTR) amyloidosis primarily affects individuals of African descent in the U.S., but a cluster of cases has been found in white Italians.
- A study comparing Black and white individuals with Val122Ile TTR cardiac amyloidosis revealed that Black patients exhibited lower blood pressure and impaired renal function, alongside distinct differences in cardiac chamber performance.
- Despite similar ages at diagnosis, Black patients experienced worse cardiac dysfunction due to reduced ventricular capacitance, indicating a need for further research to determine if these differences stem from amyloidosis or other cardiovascular factors.
Transthyretin amyloidosis involves the deposition of transthyretin amyloid fibrils in the body. We report an unusual case of a young Afro-Caribbean woman harboring a Thr60Ala mutation who presented with clinical signs of heart failure and polyneuropathy confirmed with genetic testing and results of an abdominal fat pad biopsy. ().
View Article and Find Full Text PDFBackground: With increasing diagnoses and available treatment options for transthyretin amyloidosis cardiomyopathy (ATTR-CM), risk stratification of ATTR-CM patients is imperative.
Objectives: We hypothesized that diuretic dose and New York Heart Association (NYHA) functional class are independent predictors of mortality in ATTR-CM and would be incrementally additive to existent risk scores.
Methods: Consecutive ATTR-CM patients referred to a single center were identified.
Article Synopsis
- Transthyretin cardiac amyloidosis (ATTR-CA) is a lesser-known condition that can lead to heart failure, with the Val122Ile genetic variant being the most common in the U.S.
- A study involving 73 patients revealed that women were diagnosed at an older age than men (76 vs. 69 years), but both sexes showed similar heart function and mortality rates after 3 years.
- The results imply that while women may be older at diagnosis, they experience a less severe form of the disease compared to men, warranting further research for confirmation.
Article Synopsis
- Atrial fibrillation (AF) is prevalent in patients with transthyretin cardiac amyloidosis (ATTR-CA), and there's no clear best way to prevent strokes in these patients.
- A study compared outcomes for patients with ATTR-CA and AF who were treated with warfarin versus those treated with novel oral anticoagulants (NOACs), analyzing data from 290 patients.
- Results showed that while patients with AF had a higher risk of thrombotic events, there was no significant difference in stroke, major bleeding, or death between those taking warfarin and those on NOACs during a follow-up period.
Article Synopsis
- Light-chain cardiac amyloidosis (AL CA) has a poorer survival prognosis compared to transthyretin cardiac amyloidosis (ATTR CA) after heart transplantation (OHT).
- A study comparing survival rates of 39 CA patients (18 AL and 21 ATTR) and 1023 non-amyloidosis patients showed significantly lower survival rates for AL in the early era of OHT (2001-2007).
- However, in the late era (2008-2018), survival rates for AL and ATTR patients improved and became similar to those of non-amyloidosis patients, indicating diminished differences in post-OHT survival outcomes.
Article Synopsis
- * A study analyzed survival differences among 300 patients based on nutritional status (using modified BMI) and inflammatory status (measured by serum uric acid) to see how they impacted mortality rates.
- * Results indicated that lower modified BMI and higher serum uric acid levels were both associated with shorter survival times, with those having both low BMI and high uric acid having the worst outcomes.